Company Interview / Recce Pharmaceuticals combating global threats with US Army

James Graham, CEO from Recce Pharmaceuticals (ASX:RCE) shares the company's latest collaboration with the US Army's Infectious Diseases Institute. This partnership focuses on developing solutions for both military and civilian pathogenic threats. It signifies a step forward in their antibacterial research.

Recce's (ASX:RCE) compound was well-received in phase two trials for burn wound infections, showcasing efficacy and tolerance. They now aim to further test their compound on significant pathogenic threats like anthrax and plague. If successful, this could lead to substantial commercial opportunities.

James mentions a positive strategic direction with ongoing projects for diabetic foot ulcers in Indonesia and other US government engagements. With recent shareholder interest boosting their financial position, Recce is poised to embrace major market opportunities, especially in the antibiotic sector.